Back to Results
First PageMeta Content
ViiV Healthcare / Intel Viiv / Prescription Drug User Fee Act / Shionogi / Integrase inhibitor / Food and Drug Administration / Integrase / Pharmaceutical sciences / Pharmacology / Clinical research


Document Date: 2014-11-03 11:26:09

Open Document

File Size: 34,00 KB

Share Result on Facebook

City

Osaka / London / /

Company

Shionogi-ViiV Healthcare LLC / ViiV Healthcare Ltd. / Shionogi & Co. Ltd. / Corporate Communications Shionogi & Co. Ltd. / /

Country

Japan / United States / Canada / /

Event

FDA Phase / Business Partnership / /

/

IndustryTerm

foreign healthcare reforms / with respect to product / /

MedicalCondition

HIV infection / HIV / /

Organization

FDA / European Union / United States Food and Drug Administration / /

Person

Isao Teshirogi / Dominique Limet / /

/

Position

President & CEO / Chief Executive Officer / /

Product

Prescription Drug / Tivicay / Tivicay® / Integrase Inhibitor Tivicay® (dolutegravir) / /

SocialTag